In the case of MDS, attempts at further harnessing the strength of the immune system to target clones came in the form of immune checkpoint inhibitors (PD-L1, CTLA-4, and CD47), but failed to show improvement over HMAs. Here, CTLA4 is linked to myelodysplastic syndrome.